Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2018-06-01
|
| Series: | Journal of Renal and Hepatic Disorders |
| Subjects: | |
| Online Access: | https://jrenhep.com/index.php/jrenhep/article/view/33 |
| _version_ | 1818255621502271488 |
|---|---|
| author | Nicole Marie Lioufas Alan Street Paul Champion de Crespigny Stephen G Holt |
| author_facet | Nicole Marie Lioufas Alan Street Paul Champion de Crespigny Stephen G Holt |
| author_sort | Nicole Marie Lioufas |
| collection | DOAJ |
| description | Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity. |
| first_indexed | 2024-12-12T17:14:46Z |
| format | Article |
| id | doaj.art-7368840b7ccf4c4cb42ecb938751d635 |
| institution | Directory Open Access Journal |
| issn | 2207-3744 |
| language | English |
| last_indexed | 2024-12-12T17:14:46Z |
| publishDate | 2018-06-01 |
| publisher | Codon Publications |
| record_format | Article |
| series | Journal of Renal and Hepatic Disorders |
| spelling | doaj.art-7368840b7ccf4c4cb42ecb938751d6352022-12-22T00:17:48ZengCodon PublicationsJournal of Renal and Hepatic Disorders2207-37442018-06-012210.15586/jrenhep.2018.3319Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIVNicole Marie Lioufas0Alan Street1Paul Champion de Crespigny2Stephen G Holt3Department of Nephrology Royal Melbourne Hospital Parkville, AustraliaVictorian Infectious Diseases Service, The Royal Melbourne Hospital Parkville, AustraliaDepartment of Nephrology Royal Melbourne Hospital Parkville, AustraliaDepartment of Nephrology Royal Melbourne Hospital Parkville, AustraliaTenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity.https://jrenhep.com/index.php/jrenhep/article/view/33TenofovirtubulopathiesHIV |
| spellingShingle | Nicole Marie Lioufas Alan Street Paul Champion de Crespigny Stephen G Holt Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV Journal of Renal and Hepatic Disorders Tenofovir tubulopathies HIV |
| title | Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV |
| title_full | Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV |
| title_fullStr | Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV |
| title_full_unstemmed | Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV |
| title_short | Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV |
| title_sort | monitoring the effects of tenofovir disoproxil fumarate to tenofovir alafenamide switch for tubulotoxicity in highly treatment experienced or in very sick individuals infected with hiv |
| topic | Tenofovir tubulopathies HIV |
| url | https://jrenhep.com/index.php/jrenhep/article/view/33 |
| work_keys_str_mv | AT nicolemarielioufas monitoringtheeffectsoftenofovirdisoproxilfumaratetotenofoviralafenamideswitchfortubulotoxicityinhighlytreatmentexperiencedorinverysickindividualsinfectedwithhiv AT alanstreet monitoringtheeffectsoftenofovirdisoproxilfumaratetotenofoviralafenamideswitchfortubulotoxicityinhighlytreatmentexperiencedorinverysickindividualsinfectedwithhiv AT paulchampiondecrespigny monitoringtheeffectsoftenofovirdisoproxilfumaratetotenofoviralafenamideswitchfortubulotoxicityinhighlytreatmentexperiencedorinverysickindividualsinfectedwithhiv AT stephengholt monitoringtheeffectsoftenofovirdisoproxilfumaratetotenofoviralafenamideswitchfortubulotoxicityinhighlytreatmentexperiencedorinverysickindividualsinfectedwithhiv |